Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness.
This report elaborates on the current development of the Duchenne Muscular Dystrophy Drug industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
By Player:
Nobelpharma
Catabasis Pharmaceuticals
Eli Lilly
Pfizer
Marathon Pharmaceuticals
PTC Therapeutics
Bristol-Myers Squibb
Santhera Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
Akashi Therapeutics
Janssen Pharmaceuticals
Asklepios BioPharmaceuticals
Lexicon Pharmaceuticals
Acceleron Pharma
By Type:
Mutation Suppression
Steroid Therapy
Exon Skipping
By Application:
EXONDYS 51
Emflaza
Translarna
By Research Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
Chapter 1 China Duchenne Muscular Dystrophy Drug Market Overview 2018-2029
-
1.1 China Duchenne Muscular Dystrophy Drug Industry Development Overview
-
1.2 China Duchenne Muscular Dystrophy Drug Industry Development History
-
1.3 China Duchenne Muscular Dystrophy Drug Industry Market Size (2018-2029)
-
1.4 China Duchenne Muscular Dystrophy Drug Market Analysis by Type from Production Side
-
1.4.1 China Duchenne Muscular Dystrophy Drug Production Volume, Production Value and Growth Rate of Mutation Suppression (2018-2029)
-
1.4.2 China Duchenne Muscular Dystrophy Drug Production Volume, Production Value and Growth Rate of Steroid Therapy (2018-2029)
-
1.4.3 China Duchenne Muscular Dystrophy Drug Production Volume, Production Value and Growth Rate of Exon Skipping (2018-2029)
-
1.5 China Duchenne Muscular Dystrophy Drug Market Analysis by Application from Consumption End
-
1.5.1 China Duchenne Muscular Dystrophy Drug Sales Volume, Sales Value and Growth Rate of EXONDYS 51 (2018-2029)
-
1.5.2 China Duchenne Muscular Dystrophy Drug Sales Volume, Sales Value and Growth Rate of Emflaza (2018-2029)
-
1.5.3 China Duchenne Muscular Dystrophy Drug Sales Volume, Sales Value and Growth Rate of Translarna (2018-2029)
-
1.6 China Duchenne Muscular Dystrophy Drug Market Analysis by Region
-
1.6.1 North China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
1.6.2 Central China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
1.6.3 South China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
1.6.4 East China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
1.6.5 Northeast China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
1.6.6 Southwest China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
1.6.7 Northwest China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
Chapter 2 China Duchenne Muscular Dystrophy Drug Industry Development Environment
-
2.1 Industry Development Environment Analysis
-
2.1.1 Industry Technological Progress Analysis
-
2.1.2 Industrial Organizational Innovation Analysis
-
2.1.3 Changes in Social Habits
-
2.1.4 Alterations in Government Policies
-
2.1.5 Impact of Economic Globalization
-
2.2 Domestic and Foreign Industry Competition Analysis
-
2.2.1 Comparative Analysis on Duchenne Muscular Dystrophy Drug Market Status and Competition at home and abroad in 2023
-
2.2.2 China Duchenne Muscular Dystrophy Drug Market Status and Competition Analysis in 2023
-
2.2.3 China Duchenne Muscular Dystrophy Drug Market Concentration Analysis in 2023
-
2.3 Problems and Countermeasures in the development of China Duchenne Muscular Dystrophy Drug Industry
-
2.3.1 Industry Development Constraints
-
2.3.2 Industry Development Considerations
-
2.3.3 Suggestions on Industry Development Measures
-
2.3.4 Development Strategies for SMEs
-
2.4 Influence of COVID-19 Outbreak on Duchenne Muscular Dystrophy Drug Industry Development
Chapter 3 Duchenne Muscular Dystrophy DrugIndustry Chain Analysis
-
3.1 Duchenne Muscular Dystrophy Drug Industry Chain
-
3.2 Duchenne Muscular Dystrophy Drug Upstream Industry Analysis
-
3.2.1 Upstream Industry Development Status
-
3.2.2 Upstream Industry Development Forecast
-
3.2.3 Impact of Upstream Industry on the Duchenne Muscular Dystrophy Drug Market
-
3.3 Duchenne Muscular Dystrophy Drug Downstream Industry Analysis
-
3.3.1 Downstream Industry Development Status
-
3.3.2 Downstream Industry Development Forecast
-
3.3.3 Impact of Downstream Industry on the Duchenne Muscular Dystrophy Drug Market
Chapter 4 China Duchenne Muscular Dystrophy Drug Market, by Type
-
4.1 China Duchenne Muscular Dystrophy Drug Market Trend, by Type
-
4.2 Product Types of Major Suppliers
-
4.3 Competitive Landscape of Major Types
-
4.4 China Duchenne Muscular Dystrophy Drug Total Production Volume and Growth Rate from Production Side
-
4.5 China Duchenne Muscular Dystrophy Drug Production Volume and Growth Rate, by Type
-
4.5.1 China Duchenne Muscular Dystrophy Drug Production Volume and Growth Rate of Mutation Suppression
-
4.5.2 China Duchenne Muscular Dystrophy Drug Production Volume and Growth Rate of Steroid Therapy
-
4.5.3 China Duchenne Muscular Dystrophy Drug Production Volume and Growth Rate of Exon Skipping
Chapter 5 China Duchenne Muscular Dystrophy Drug Market, by Application
-
5.1 Downstream Market Overview
-
5.2 Competitive Landscape of Major Applications
-
5.3 Market Potential Analysis, by Application
-
5.4 China Duchenne Muscular Dystrophy Drug Total Market Size and Growth Rate from Consumption End
-
5.5 China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate, by Application
-
5.5.1 China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate of EXONDYS 51
-
5.5.2 China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate of Emflaza
-
5.5.3 China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate of Translarna
Chapter 6 China Duchenne Muscular Dystrophy Drug Market, by Region
-
6.1 China Duchenne Muscular Dystrophy Drug Production Volume and Production Value, by Region
-
6.2 China Duchenne Muscular Dystrophy Drug Sales Volume and Sales Value, by Region
Chapter 7 North China Duchenne Muscular Dystrophy Drug Market Analysis
-
7.1 North China Duchenne Muscular Dystrophy Drug Market, by Type
-
7.2 North China Duchenne Muscular Dystrophy Drug Market, by Application
Chapter 8 Central China Duchenne Muscular Dystrophy Drug Market Analysis
-
8.1 Central China Duchenne Muscular Dystrophy Drug Market, by Type
-
8.2 Central China Duchenne Muscular Dystrophy Drug Market, by Application
Chapter 9 South China Duchenne Muscular Dystrophy Drug Market Analysis
-
9.1 South China Duchenne Muscular Dystrophy Drug Market, by Type
-
9.2 South China Duchenne Muscular Dystrophy Drug Market, by Application
Chapter 10 East China Duchenne Muscular Dystrophy Drug Market Analysis
-
10.1 East China Duchenne Muscular Dystrophy Drug Market, by Type
-
10.2 East China Duchenne Muscular Dystrophy Drug Market, by Application
Chapter 11 Northeast China Duchenne Muscular Dystrophy Drug Market Analysis
-
11.1 Northeast China Duchenne Muscular Dystrophy Drug Market, by Type
-
11.2 Northeast China Duchenne Muscular Dystrophy Drug Market, by Application
Chapter 12 Southwest China Duchenne Muscular Dystrophy Drug Market Analysis
-
12.1 Southwest China Duchenne Muscular Dystrophy Drug Market, by Type
-
12.2 Southwest China Duchenne Muscular Dystrophy Drug Market, by Application
Chapter 13 Northwest China Duchenne Muscular Dystrophy Drug Market Analysis
-
13.1 Northwest China Duchenne Muscular Dystrophy Drug Market, by Type
-
13.2 Northwest China Duchenne Muscular Dystrophy Drug Market, by Application
Chapter 14 Company Profiles
-
14.1 Nobelpharma
-
14.1.1 Nobelpharma Company Profile
-
14.1.2 Nobelpharma Duchenne Muscular Dystrophy Drug Market Performance
-
14.1.3 Product&Service Introduction
-
14.2 Catabasis Pharmaceuticals
-
14.2.1 Catabasis Pharmaceuticals Company Profile
-
14.2.2 Catabasis Pharmaceuticals Duchenne Muscular Dystrophy Drug Market Performance
-
14.2.3 Product&Service Introduction
-
14.3 Eli Lilly
-
14.3.1 Eli Lilly Company Profile
-
14.3.2 Eli Lilly Duchenne Muscular Dystrophy Drug Market Performance
-
14.3.3 Product&Service Introduction
-
14.4 Pfizer
-
14.4.1 Pfizer Company Profile
-
14.4.2 Pfizer Duchenne Muscular Dystrophy Drug Market Performance
-
14.4.3 Product&Service Introduction
-
14.5 Marathon Pharmaceuticals
-
14.5.1 Marathon Pharmaceuticals Company Profile
-
14.5.2 Marathon Pharmaceuticals Duchenne Muscular Dystrophy Drug Market Performance
-
14.5.3 Product&Service Introduction
-
14.6 PTC Therapeutics
-
14.6.1 PTC Therapeutics Company Profile
-
14.6.2 PTC Therapeutics Duchenne Muscular Dystrophy Drug Market Performance
-
14.6.3 Product&Service Introduction
-
14.7 Bristol-Myers Squibb
-
14.7.1 Bristol-Myers Squibb Company Profile
-
14.7.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Drug Market Performance
-
14.7.3 Product&Service Introduction
-
14.8 Santhera Pharmaceuticals
-
14.8.1 Santhera Pharmaceuticals Company Profile
-
14.8.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drug Market Performance
-
14.8.3 Product&Service Introduction
-
14.9 Sarepta Therapeutics
-
14.9.1 Sarepta Therapeutics Company Profile
-
14.9.2 Sarepta Therapeutics Duchenne Muscular Dystrophy Drug Market Performance
-
14.9.3 Product&Service Introduction
-
14.10 Nippon Shinyaku
-
14.10.1 Nippon Shinyaku Company Profile
-
14.10.2 Nippon Shinyaku Duchenne Muscular Dystrophy Drug Market Performance
-
14.10.3 Product&Service Introduction
-
14.11 Akashi Therapeutics
-
14.11.1 Akashi Therapeutics Company Profile
-
14.11.2 Akashi Therapeutics Duchenne Muscular Dystrophy Drug Market Performance
-
14.11.3 Product&Service Introduction
-
14.12 Janssen Pharmaceuticals
-
14.12.1 Janssen Pharmaceuticals Company Profile
-
14.12.2 Janssen Pharmaceuticals Duchenne Muscular Dystrophy Drug Market Performance
-
14.12.3 Product&Service Introduction
-
14.13 Asklepios BioPharmaceuticals
-
14.13.1 Asklepios BioPharmaceuticals Company Profile
-
14.13.2 Asklepios BioPharmaceuticals Duchenne Muscular Dystrophy Drug Market Performance
-
14.13.3 Product&Service Introduction
-
14.14 Lexicon Pharmaceuticals
-
14.14.1 Lexicon Pharmaceuticals Company Profile
-
14.14.2 Lexicon Pharmaceuticals Duchenne Muscular Dystrophy Drug Market Performance
-
14.14.3 Product&Service Introduction
-
14.15 Acceleron Pharma
-
14.15.1 Acceleron Pharma Company Profile
-
14.15.2 Acceleron Pharma Duchenne Muscular Dystrophy Drug Market Performance
-
14.15.3 Product&Service Introduction
Chapter 15 Research Conclusions and Investment Suggestions
-
15.1 Duchenne Muscular Dystrophy Drug Industry Research Conclusions
-
15.2 Duchenne Muscular Dystrophy Drug Industry Investment Suggestions
-
15.2.1 Suggestions on Industry Development Strategy
-
15.2.2 Suggestions on Industry Investment Direction
-
15.2.3 Suggestions on Industry Investment Strategy
List of Tables and Figures
-
Figure China Duchenne Muscular Dystrophy Drug Industry Market Size (2018-2029)
-
Figure China Duchenne Muscular Dystrophy Drug Production Volume, Production Value and Growth Rate of Mutation Suppression (2018-2029)
-
Figure China Duchenne Muscular Dystrophy Drug Production Volume, Production Value and Growth Rate of Steroid Therapy (2018-2029)
-
Figure China Duchenne Muscular Dystrophy Drug Production Volume, Production Value and Growth Rate of Exon Skipping (2018-2029)
-
Figure China Duchenne Muscular Dystrophy Drug Sales Volume, Sales Value and Growth Rate of EXONDYS 51 (2018-2029)
-
Figure China Duchenne Muscular Dystrophy Drug Sales Volume, Sales Value and Growth Rate of Emflaza (2018-2029)
-
Figure China Duchenne Muscular Dystrophy Drug Sales Volume, Sales Value and Growth Rate of Translarna (2018-2029)
-
Figure North China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
Figure Central China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
Figure South China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
Figure East China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
Figure Northeast China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
Figure Southwest China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
Figure Northwest China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate from 2018-2029
-
Figure Duchenne Muscular Dystrophy Drug Industry Chain
-
Table Product Types of Major Suppliers in 2023
-
Figure China Duchenne Muscular Dystrophy Drug Market Share by Type in 2018
-
Figure China Duchenne Muscular Dystrophy Drug Market Share by Type in 2023
-
Figure China Duchenne Muscular Dystrophy Drug Total Production Volume and Growth Rate from Production Side (2018-2023)
-
Figure China Duchenne Muscular Dystrophy Drug Production Volume and Growth Rate of Mutation Suppression (2018-2023)
-
Figure China Duchenne Muscular Dystrophy Drug Production Volume and Growth Rate of Steroid Therapy (2018-2023)
-
Figure China Duchenne Muscular Dystrophy Drug Production Volume and Growth Rate of Exon Skipping (2018-2023)
-
Figure China Duchenne Muscular Dystrophy Drug Market Share by Application in 2018
-
Figure China Duchenne Muscular Dystrophy Drug Market Share by Application in 2023
-
Figure China Duchenne Muscular Dystrophy Drug Total Market Size and Growth Rate from Consumption End
-
Figure China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate of EXONDYS 51 (2018-2023)
-
Figure China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate of Emflaza (2018-2023)
-
Figure China Duchenne Muscular Dystrophy Drug Market Size and Growth Rate of Translarna (2018-2023)
-
Table China Duchenne Muscular Dystrophy Drug Production Volume by Region (2018-2023)
-
Table China Duchenne Muscular Dystrophy Drug Production Volume Share by Region (2018-2023)
-
Figure China Duchenne Muscular Dystrophy Drug Production Volume Share by Region (2018-2023)
-
Table China Duchenne Muscular Dystrophy Drug Production Value by Region (2018-2023)
-
Table China Duchenne Muscular Dystrophy Drug Production Value Share by Region (2018-2023)
-
Figure China Duchenne Muscular Dystrophy Drug Production Value Share by Region (2018-2023)
-
Table China Duchenne Muscular Dystrophy Drug Sales Volume by Region (2018-2023)
-
Table China Duchenne Muscular Dystrophy Drug Sales Volume Share by Region (2018-2023)
-
Figure China Duchenne Muscular Dystrophy Drug Sales Volume Share by Region (2018-2023)
-
Table China Duchenne Muscular Dystrophy Drug Sales Value by Region (2018-2023)
-
Table China Duchenne Muscular Dystrophy Drug Sales Value Share by Region (2018-2023)
-
Figure China Duchenne Muscular Dystrophy Drug Sales Value Share by Region (2018-2023)
-
Table North China Duchenne Muscular Dystrophy Drug Production Volume by Type (2018-2023)
-
Table North China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Figure North China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Table North China Duchenne Muscular Dystrophy Drug Sales Volume by Application (2018-2023)
-
Table North China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Figure North China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Table Central China Duchenne Muscular Dystrophy Drug Production Volume by Type (2018-2023)
-
Table Central China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Figure Central China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Table Central China Duchenne Muscular Dystrophy Drug Sales Volume by Application (2018-2023)
-
Table Central China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Figure Central China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Table South China Duchenne Muscular Dystrophy Drug Production Volume by Type (2018-2023)
-
Table South China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Figure South China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Table South China Duchenne Muscular Dystrophy Drug Sales Volume by Application (2018-2023)
-
Table South China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Figure South China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Table East China Duchenne Muscular Dystrophy Drug Production Volume by Type (2018-2023)
-
Table East China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Figure East China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Table East China Duchenne Muscular Dystrophy Drug Sales Volume by Application (2018-2023)
-
Table East China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Figure East China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Table Northeast China Duchenne Muscular Dystrophy Drug Production Volume by Type (2018-2023)
-
Table Northeast China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Figure Northeast China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Table Northeast China Duchenne Muscular Dystrophy Drug Sales Volume by Application (2018-2023)
-
Table Northeast China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Figure Northeast China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Table Southwest China Duchenne Muscular Dystrophy Drug Production Volume by Type (2018-2023)
-
Table Southwest China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Figure Southwest China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Table Southwest China Duchenne Muscular Dystrophy Drug Sales Volume by Application (2018-2023)
-
Table Southwest China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Figure Southwest China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Table Northwest China Duchenne Muscular Dystrophy Drug Production Volume by Type (2018-2023)
-
Table Northwest China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Figure Northwest China Duchenne Muscular Dystrophy Drug Production Volume Share by Type (2018-2023)
-
Table Northwest China Duchenne Muscular Dystrophy Drug Sales Volume by Application (2018-2023)
-
Table Northwest China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Figure Northwest China Duchenne Muscular Dystrophy Drug Sales Volume Share by Application (2018-2023)
-
Table Nobelpharma Company Profile
-
Table Nobelpharma Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Catabasis Pharmaceuticals Company Profile
-
Table Catabasis Pharmaceuticals Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Eli Lilly Company Profile
-
Table Eli Lilly Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Pfizer Company Profile
-
Table Pfizer Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Marathon Pharmaceuticals Company Profile
-
Table Marathon Pharmaceuticals Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table PTC Therapeutics Company Profile
-
Table PTC Therapeutics Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Bristol-Myers Squibb Company Profile
-
Table Bristol-Myers Squibb Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Santhera Pharmaceuticals Company Profile
-
Table Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Sarepta Therapeutics Company Profile
-
Table Sarepta Therapeutics Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Nippon Shinyaku Company Profile
-
Table Nippon Shinyaku Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Akashi Therapeutics Company Profile
-
Table Akashi Therapeutics Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Janssen Pharmaceuticals Company Profile
-
Table Janssen Pharmaceuticals Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Asklepios BioPharmaceuticals Company Profile
-
Table Asklepios BioPharmaceuticals Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Lexicon Pharmaceuticals Company Profile
-
Table Lexicon Pharmaceuticals Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
Table Acceleron Pharma Company Profile
-
Table Acceleron Pharma Duchenne Muscular Dystrophy Drug Revenue, Price and Gross (2018-2023)
-
